DOI:
10.1055/s-00000133
Gastroenterologie up2date
LinksClose Window
References
Schmiegel WH, Reinacher-Schick A, Freier W. et al.
Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) versus capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI Tumor Study Group.
ASCO Annual Meeting Proceedings J Clin Oncol 2007; 25: 18S (Abstr 4034)-
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.